Astellas Pharma (OTCMKTS:ALPMY) Upgraded to “Hold” at Smbc Nikko Sec.

Astellas Pharma (OTCMKTS:ALPMY) was upgraded by equities researchers at Smbc Nikko Sec. to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Several other equities analysts have also commented on ALPMY. Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Citigroup lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 19th. Four equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, Astellas Pharma has a consensus rating of “Hold”.

Astellas Pharma Stock Down 3.6%

Shares of ALPMY stock opened at $15.90 on Monday. Astellas Pharma has a 1-year low of $8.37 and a 1-year high of $16.95. The stock’s fifty day moving average price is $14.23 and its 200 day moving average price is $12.37. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.03 and a quick ratio of 0.80. The company has a market cap of $28.77 billion, a price-to-earnings ratio of 13.36 and a beta of 0.18.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.29 by $0.15. The company had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.21 billion. Astellas Pharma had a return on equity of 24.24% and a net margin of 15.63%. On average, research analysts expect that Astellas Pharma will post 0.42 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).